Viva Biotech
Overview
Viva Biotech is a global biopharmaceutical service and investment firm that provides integrated drug discovery and development services while operating a unique equity-for-service (EFS) investment model to support early-stage biotech startups.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| VivaVision Biotech | Apr 2021 | Series D | - |
| Mediar Therapeutics | Mar 2023 | Series A | - |
| Shanghai Bima Life Sciences | Jan 2019 | Series A | Co-investor |
| WMT AG | - | Seed | Co-investor |
| Antag Therapeutics | Dec 2024 | Series A | - |
For institutional investors. Book with your work email.
Key People
Yinghong Gao
Venture Partner & VP of BD
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Viva Biotech based?
Viva Biotech is headquartered in Shanghai, China.
When was Viva Biotech founded?
Viva Biotech was founded in 2008.
How many portfolio companies does Viva Biotech have?
Viva Biotech has 14 portfolio companies in Caplight's dataset.
What are some companies in Viva Biotech's portfolio?
Portfolio companies visible on Caplight include VivaVision Biotech, Mediar Therapeutics, Shanghai Bima Life Sciences, WMT AG, Antag Therapeutics.
What was Viva Biotech's most recent investment shown here?
Viva Biotech's most recent investment in this portfolio sample was in Antag Therapeutics in 2024.
What sectors does Viva Biotech focus on?
Viva Biotech focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Viva Biotech focus on?
Viva Biotech typically invests at the Early stage.
What is Viva Biotech's AUM?
Viva Biotech's assets under management are estimated between $250.0M and $500.0M.